AirSculpt Technologies, Inc.

Greetings and welcome to the AirSculpt Technologies second quarter fiscal 2024 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. I would now like to turn the conference over to your host, Allison Malkin with ICR. Thank you. You may begin.

Good morning, everyone. Thank you for joining us to discuss AirScope Technologies' results for the second quarter of fiscal 2024. Joining me on the call today are the company's founder and executive chairman, Dr. Aaron Rollins, and interim chief executive officer and chief financial officer, Dennis Dean. Before we begin, I would like to remind you that this conference call may include forward-looking statements. These statements may include our future expectations regarding financial results and guidance, market opportunities, and our growth. Risks and uncertainties that may impact these statements and could cause actual future results to differ materially from currently projected results are described in this morning's press release and the reports we will file with the SEC, all of which can be found on our website at investors.airsculpt.com. We undertake no obligation to revise or update any forward-looking statements or information except as required by law. During this call, we will also reference certain non-GAAP financial measures. We use non-GAAP measures in some of our financial discussions as we believe they more accurately represent the true operational performance and underlying results of our business. A reconciliation of these measures can be found in our earnings release as filed this morning and in our most recent 10Q, which also will be available on our website. With that, I'll turn the call over to Dr. Rollins.

Good morning, everyone, and thank you for joining today's call. Earlier this morning, we announced second quarter results below our expectations amid a challenging demand backdrop. Despite these results, we remain committed to reestablishing our same store growth trajectory, opening and ramping our de novo centers, and improving our operating margins. To achieve these objectives, the management team's current focus is on back to basics. For us, that means investing prudently in our performance marketing efforts, providing the best experience for our patients, and letting our doctors do what they are expertly trained to do. which has performed best-in-class body contouring procedures using our proprietary AirSculpt technology. This morning, we also announced a series of management changes. Effective today, Dennis Dean will serve as our interim CEO, in addition to his ongoing role as CFO, as we work with a top-tier global executive search firm to lead our search for a permanent CEO. Dennis' proven financial acumen discipline leadership style, and passion for our firm's patient-centric mission will enable the company to improve performance as we pursue our back-to-basics approach. I will remain in my position as founder and executive chair. In this role, I'll continue to provide strategic guidance and clinical leadership gain from my 20 years of experience in the industry as a surgeon as well as a company executive. Before I turn the call over to Dennis, I would just like to comment on our very strong track record, having successfully completed more than 60,000 procedures since I founded the company in 2012. Our positive performance record, the proprietary technology we possess, and the large addressable market with which we operate in provides us with a vast opportunity from which to grow. We look forward to updating you on our progress as we dedicate our efforts to improving near-term performance and to building long-term shareholder value. I'll now turn the call over to Dennis to provide more details on the quarter, as well as our outlook for the year.